Makoto Iwasaki

Makoto Iwasaki

Auto-generated profile, based on publicly available information

Makoto Iwasaki

Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
TTTomoko Toyosaki
Tomoko Toyosaki
TYTakeshi Yoshioka
Takeshi Yoshioka
YTYuji Tsuruta
Yuji Tsuruta
TYTakashi Yutsudo
Takashi Yutsudo
MIMakoto Iwasaki
Makoto Iwasaki
RSRyuji Suzuki
Ryuji Suzuki

31 January 2025 in Blood Advances
Verified
Journal Article
Open access
JHJessy Xinyi Han
Jessy Xinyi Han
MKMin Jung Koh
Min Jung Koh
LBLeora Boussi
Leora Boussi
MSMark Sorial
Mark Sorial
SMSean M McCabe
Sean M McCabe
SJSalvia Jain
Salvia Jain
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer–cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma–not otherwise specified and anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK– ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.

1 September 1994 in Infection and Immunity
Verified
Journal Article
Open access
TYT Yutsudo
T Yutsudo
KOK Okumura
K Okumura
MIM Iwasaki
M Iwasaki
AHA Hara
A Hara
SKShigeki Kamitani
Shigeki Kamitani
YHY Hinuma
Y Hinuma
We recently cloned a gene encoding a new mitogenic factor (MF) from Streptococcus pyogenes NY-5. In the present study, we determined the distribution of this MF gene (mf) by PCR based upon its sequence. Of 371 streptococcal group A strains isolated from clinical specimens, 370 (99.7%) were positive for mf. The strain that was negative for the MF gene was also negative for the streptolysin O gene (slo). Some streptococcal strains belonging to groups C and G were negative for mf but positive for slo. Group B strains were negative for both. Furthermore, we examined the presence of mf in 54 strains belonging to 28 families and found mf only in group A streptococci. These results indicate that mf is distributed specifically in group A streptococci and the presence of mf in clinical samples strongly suggests infection with group A streptococci.

18 August 2025 in Blood Advances
Verified
Journal Article
Open access
JFJosie G. Ford
Josie G. Ford
MKMin Jung Koh
Min Jung Koh
ALAlexandra W. Lenart
Alexandra W. Lenart
CMCaroline MacVicar
Caroline MacVicar
KCKusha Chopra
Kusha Chopra
SJSalvia Jain
Salvia Jain
Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) require lineage-specific therapies to bridge to hematopoietic stem cell transplantation (HSCT). A previous phase 1/2 study of duvelisib/romidepsin (duv/romi) reported an overall response rate (ORR) of 58% and a complete response rate (CRR) of 42% with reduced grade 3 to 4 transaminitis (14%). We report real-world duv/romi outcomes in a multicenter, 38-patient R/R PTCL cohort. The median age at diagnosis was 62 years. Histological subtypes included nodal T follicular helper cell (nTFH; n = 17), PTCL-not otherwise specified (n = 14), cutaneous T-cell lymphoma (TCL; n = 3), extranodal natural killer/TCL (n = 1), ALK-negative anaplastic large cell lymphoma (n = 1), adult T-cell leukemia/lymphoma (n = 1), and hepatosplenic TCL (n = 1). The median previous therapy count was 1 (interquartile range [IQR], 1-2); 15 patients relapsed and 23 were refractory to prior treatment, including 8 prior HSCT (5 autologous, 3 allogeneic). After a median of 3 cycles (IQR, 2-4), ORR and CRR were 61% and 47%, respectively, with higher ORR (82% vs 43%) and CRR (71% vs 29%) in nTFH versus non-nTFH. The median progression-free survival and overall survival (HSCT-censored) were 11 and 16 months for nTFH, versus 3.3 and 8.3 months for non-nTFH. The median time to response was 1.9 months (IQR, 1.7-2.6), duration of response was 21 months, and time to next therapy was 17 months. After duv/romi, 11 patients bridged to allo-HSCT. Treatment was well tolerated; the most common grade 3 to 4 toxicities were lymphopenia (n = 15), neutropenia (n = 15), thrombocytopenia (n = 10), and transaminitis (n = 6), seldom leading to discontinuation (n = 4) or death (n = 1). These findings reinforce duv/romi’s efficacy and bridging role to curative HSCT in high-risk R/R PTCL.

8 July 2026 in Nature
Verified
Journal Article
Open access
PDF file
YOYotaro Ochi
Yotaro Ochi
MLMarkus Liew-Littorin
Markus Liew-Littorin
YNYasuhito Nannya
Yasuhito Nannya
SBSofia Bengtzen
Sofia Bengtzen
BPBenedicte Piauger
Benedicte Piauger
SOSeishi Ogawa
Seishi Ogawa
Acute myeloid leukaemia (AML) is an aggressive blood cancer characterized by the unregulated proliferation of immature myeloblasts. Gene mutations have been shown to have a large effect on pathogenesis, inter-tumour heterogeneity and clinical outcomes in AML1,2,3,4,5,6,7,8; however, the role of epigenetic alterations in these respects has been investigated less extensively. Here we use ATAC-seq (assay for transposase-accessible chromatin with sequencing) in a cohort of 1,563 individuals with a recent diagnosis of AML (the ‘eCHROMA’ cohort) to show that AML can be classified into 16 subgroups on the basis of chromatin accessibility profiles. Multiomics analyses of gene mutations, the transcriptome, DNA methylation and histone marks show that these ATAC subgroups exhibit distinct driver mutations, differentiation states, gene expression, DNA methylation and super-enhancer profiles, and are also associated with clinical outcomes. These findings were validated in independent cohorts. Single-cell ATAC sequencing reveals that all leukaemic cells in each subgroup share a common chromatin accessibility profile, which suggests that subgroup-specific epigenomic fingerprints underlie the ATAC-based classification. Mechanistically, the subgroups have distinct gene-regulatory networks that are driven by the activities of key transcription factors in haematopoiesis, and in which subgroup-specific super-enhancers have a pivotal role. Multiomics single-cell analysis further reveals deregulated trajectories of differentiation coupled with chromatin accessibility and gene expression. Notably, ATAC subgroups have an independent prognostic effect, compared with genomic classification, and are associated with particular drug sensitivities. In summary, ATAC-based chromatin profiling, combined with multiomics data, provides insights into AML pathogenesis beyond genomics and constitutes a valuable resource for AML research.

7 January 2026 in Leukemia
Verified
Journal Article
Closed access
PDF file
KCKazuhisa Chonabayashi
Kazuhisa Chonabayashi
MIMakoto Iwasaki
Makoto Iwasaki
JKJunya Kanda
Junya Kanda
HTHiroyuki Takamori
Hiroyuki Takamori
AYAkinori Yoda
Akinori Yoda
YNYasuhito Nannya
Yasuhito Nannya